ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.
Rui Zhao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.